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Valproic acid (VPA) is an anti-convulsant drug that is recently shown to have neuroregenerative thera-
peutic actions. In this study, we investigate the underlying molecular mechanism of VPA and its effects
on Bdnf transcription through microRNAs (miRNAs) and their corresponding target proteins. Using in
silico algorithms, we predicted from our miRNA microarray and iTRAQ data that miR-124 is likely to
target at guanine nucleotide binding protein alpha inhibitor 1 (GNAI1), an adenylate cyclase inhibitor.
With the reduction of GNAI1 mediated by VPA, the cAMP is enhanced to increase Bdnf expression. The
levels of GNAI1 protein and Bdnf mRNA can be manipulated with either miR-124 mimic or inhibitor. In
summary, we have identiﬁed a novel molecular mechanism of VPA that induces miR-124 to repress
GNAI1. The implication of miR-124/GNAI1/BDNF pathway with valproic acid treatment suggests that
we could repurpose an old drug, valproic acid, as a clinical application to elevate neurotrophin levels in
treating neurodegenerative diseases.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Traditionally, valproic acid (VPA) has been a ﬁrst line of drug in
treating epilepsy and manic disorder (Henry, 2003). Over the last
decade, researchers have reported that VPA has other therapeutic
actions beside its gamma-aminobutyric acid (GABA) enhancing
effects (Rosenberg, 2007). VPA has also been shown to have efﬁcacy
in anti-tumorogenesis, neuroprotection, promoting neurogenesis,
differentiation and neuroregeneration (Abematsu et al., 2010; Foti
et al., 2013; Fukuchi et al., 2009; Hao et al., 2004; Jessberger
et al., 2007; Laeng et al., 2004; Liu et al., 2012; Morris and
Monteggia, 2013; Phiel et al., 2001). It has been reported to
induce epigenetic changes such as inhibiting histone deacetylases
(Jessberger et al., 2007; Tremolizzo et al., 2005) and microRNAs
(Goh et al., 2011; Hunsberger et al., 2012; Zhou et al., 2008) that
modulate gene expression changes post-transcriptionally. Suchory, Department of Pharma-
dical Drive 04-01 (S) 117600,
Ltd. This is an open access article uepigenetic changes regulate genes that improve synaptic plasticity
(Bredy et al., 2007; Calabrese et al., 2012; Silingardi et al., 2010).
MicroRNAs (miRNAs) are single-stranded noncoding RNAs
(ncRNAs). They are approximately 22 nucleotides long and are
cleaved by a nuclease, known as Dicer (Filipowicz et al., 2008;
Novina and Sharp, 2004). miRNA attaches to an RNA interference-
silencing complex (RISC) and is directed to the messenger RNA
(mRNA) of interest. Because of the slight imperfections in the
match between the miRNA and its recognition site, the miRNA
forms a bulge, blocking the mRNA from being translated into pro-
tein (Chuang and Jones, 2007; Gangaraju and Lin, 2009). Together
with ncRNAs, they interact with the epigenome to ﬁne-tune the
gene activity and regulate neuro-development and -physiological
network integration (Cao et al., 2007; Nelson et al., 2008). Many
miRNAs are expressed in the CNS and have been shown to regulate
neuronal development, differentiation, synaptogenesis and plas-
ticity (Edbauer et al., 2010; Fiore et al., 2011; Impey et al., 2010; Karr
et al., 2009; Makeyev et al., 2007; Vo et al., 2005; Wayman et al.,
2008; Yu et al., 2008). We have previously reported, from an in
silico angle, under the inﬂuence of VPA, miRNAs interacts specif-
ically with components of the proteineprotein interaction net-
works that affect dendritic growth and synaptic plasticity (Gohnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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branching and cortical rewiring (Lim et al., manuscript in submis-
sion) and thus hypothesized that disruption of such proteinepro-
tein networks could either be due to an increase in neurogenesis or
neuronal differentiation.
In this study, we follow up by validating global changes in
miRNAs and proteins after VPA administration taken from visual
cortices. Among the candidate miRNAs identiﬁed, miR-124 is pre-
dicted to target guanine nucleotide binding protein alpha inhibitor
1 (GNAI1). GNAI1 is an adenylate cyclase inhibitor that modulates
cAMP. Using a primary neuronal cortical culture as an in vitro
model, we found that VPA induced miR-124 which in turn,
repressed GNAI1. This consequently initiated cAMP leading to the
increase in brain-derived neurotrophic factor (Bdnf). This gives us a
better understanding of the mechanistic action of VPA. In addition,
changes in the levels and activities of BDNF have been described in
a number of neurodegenerative disorders. Using VPA could be an
experimental strategy to enhance BDNF and our dissection of the
molecular mechanism underlying VPA's effects may allow us to
design more speciﬁc targeting strategies to aid in
neuroregeneration.
2. Methods
2.1. Animals, animal welfare and ethical statement
Adult male C57BL/6 mice (postnatal age ~60 days) were used.
Animals were maintained on a 12 h light/dark cycle and had access
to food and water ad libitum. All animal protocols have been
approved by the Institutional Animal Care and Use Committee
(IACUC) in Biopolis Resource Centre, A*STAR (#120723) and Na-
tional University of Singapore (#10e101).
2.2. Drug administration
Sodium valproate (Valproic acid) (VPA; 200 mgkg1, i.p.; Sig-
maeAldrich) was dissolved in sterile saline. The same volume of
vehicle solution was injected into control animals. VPA (VPA 2d) or
vehicle solution (Veh 2d) was injected into C57BL/6 adult mice
every 12 hourly over 2 days. Visual cortices were excised 12 h after
the last injection.
2.3. Neuronal cultures
Primary neuronal cultures were prepared as described by di
Porzio et al. (1980) with minor modiﬁcations. Brieﬂy, embryonic
mouse cerebral neocortices was dissected from fetal C57BL/6 mice
at 17e18-days of gestation. The dissected tissues were incubated at
room temperature with versene (GIBCO) for 12 min followed by
mechanical dissociation. Dissociated cell suspensions were plated
at a density of 2.0  105 cells/cm2 on plastic tissue culture dish
coated with poly-L-lysine and kept in a deﬁned medium (Neuro-
basal/B-27; GIBCO) supplemented with glucose (33 mM), gluta-
mine (2 mM), penicillin (100 U/ml) and streptomycin (100 mg/ml).
Cultures weremaintained in a humidiﬁed 5% CO2 incubator at 37 C
for either 3 days in vitro (DIV) or 6 DIV with addition of 10 mM
cytosine arabinoside (Sigma Aldrich) on 2 DIV to inhibit glial pro-
liferation. Under these conditions, cultures contained ~95%
neurons.
2.4. Reagents and antibodies
in sterile saline and either vehicle or VPA was injected intra-
peritoneally at 200 mgkg1 (derived from human equivalent
dose human mg/kg dose ¼ (mouse mg/kg dose  mouse Km)/human Km) into C57BL/6 mice either 2 h after the ﬁrst drug
administration (Veh 2h or VPA 2h) or every 12 hourly over 2 days
(Veh 2d or VPA 2d). For the in vitro experiment, valproic acid
was dissolved in saline and 3 DIV primary neuronal cultures
were treated with either Veh or 5 mM VPA (concentration equiv-
alent to in vivo concentration; WinNolin software; and (Fukuchi
et al., 2009)) for 12 h prior to analysis. 100 nM of has-miR-124-3p
inhibitor (Exiqon) and 100 nM of miR-124 mimic (QIAGEN) with
their respective negative controls was applied to 3 DIV primary
neuronal culture (density of 2.0  105 cells/cm2) and incubated for
another 3 DIV before using them for experiment. For western blots,
primary antibodies-Guanine nucleotide-binding protein G(i),
alpha-1 subunit, GNAI1 (SAB2100936; Sigma Aldrich): 1:1000 for
Western Blotting (WB); beta III tubulin (b-tubulin; T0198; Sigma
Aldrich): 1:1000 for WB. Secondary antibodies-Goat anti-Rabbit
IRDye® 800CW (926e32211; Li-Cor Biosciences): 1:3000 for WB;
Alexa Fluor® 680 goat anti-mouse IgG (A21076; Invitrogen): 1:3000
for WB. For cAMP assay, cAMP was measured with High Sensitivity
Direct Cyclic AMP Chemiluminescent Immunoassay Kit
(ArborAssays).
2.5. miRNA and mRNA preparation
Total RNAwas isolated from visual cortices or primary neuronal
cultures using miRCUR™ RNA isolation kit (Exiqon). For microarray
experiment, independent pairs of visual cortices from 4 mice of
each treatment were used as biological replicates. For every miRNA
real-time quantitative PCR and mRNA real-time quantitative PCR,
independent pairs of visual cortices and primary neuronal cultures
were used as biological replicates and different set of samples from
those used in the microarray were prepared for qPCR validation.
2.6. miRNA array proﬁling
The quality of the total RNA was ﬁrst veriﬁed on an Agilent
Bioanalyzer. Total RNA (700 ng) from sample and reference were
labeled with Hy3™ and Hy5™ ﬂuorescent label, respectively, using
the miRCUR LNA™ Array power labelling kit (Exiqon) and hybrid-
ized to the miRCUR LNA™ array version 11.0 (Exiqon). After hy-
bridization, the microarray slides were scanned using the Agilent
G2565BA Microarray Scanner System (Agilent Technologies, Inc.)
and the image analysis was carried out using the ImaGene 8.0
software (BioDiscovery, Inc.), background corrected with Normexp
and normalized using the global Lowess (LOcally WEighted Scat-
terplot Smoothing) regression algorithm. Differentially expressed
miRNAs were selected via t-test comparisons of control vs treat-
ment (p-value 0.05). The expression scores were then pegged to a
color gradient map on a scale from 2 (blue, low expression) to 2
(pink, high expression). Each individual square represents a pair of
visual cortices from one biological replicate (n ¼ 4 per treatment
group).
2.7. miRNA and mRNA real time qPCR
Total RNA was converted to cDNA using miRCUR LNA™ Uni-
versal cDNA synthesis kit (Exiqon) and real-time qPCR was done
using SYBR® Green primers for hsa-miR-22, hsa-miR-33a, hsa-miR-
124, hsa-miR-132, U6 snRNA (hsa mmu), 5S rRNA (hsa), Bdnf I
forward, 50 -AGTTGCTTTGTCTTCTGTAGTCGC- 30, and reverse, 50
-CCTGGAG ACTCAGTGTCTTA- 30 and Gapdh forward 50 CTCCCAG-
GAAGACCCTGCTT 30, reverse 50 GGAACAGGGAGGAGCAGAGA 30)
and SYBR® Green master mix (Exiqon). Real-time qPCR was also
done using Taqman primers for Gnai1 (Mm01165301_m1), 18S
(Hs99999901_s1), and Gapdh (Mm99999915_g1) and Taqman
Mastermix. All RT-qPCR were done on the FAST7900HT machine
H. Oikawa et al. / Neurochemistry International 91 (2015) 62e7164(Applied Biosystems) and analyzed with RQ manager (Applied
Biosystems).
2.8. iTRAQ preparation and proﬁling
Isobaric tag for relative and absolute quantitation (iTRAQ) is a
technique that allows a comprehensive comparative quantitative
determination of protein expression (Ross et al., 2004) and we used
the protocol as previously described (Goh et al., 2011). Nuclei-
extracted proteins from Veh- and VPA-treated visual cortices
(6e8 pooled samples, 200 mg each, 2 biological replicates) were
separated via SDS-PAGE, excised, digested with trypsin and labeled
with iTRAQ tags. The tagged peptides are then separated using
Electrostatic RepulsioneHydrophobic Interaction Chromatography
(ERLIC) into 20 fractions. Each fraction was analyzed using a QStar
Elite LC-MS/MS system (AB SciEx). Proteins and peptides were
identiﬁed and quantiﬁed using ProteinPilot (Paragon) (v2.01)
against the IPI mouse database. False discovery rates was deployed
using target-decoy database search and set to 1%. The differential
scores were obtained from the signals relative to the Vehicle after
the multiplex of the Vehicle vs VPA samples and standardized cut
off of >1.2 or <0.8 are used as previously described (Goh et al.,
2011).
2.9. In silico miRNA target prediction
The candidate proteins were determined in silico from scores of
TargetScan (Friedman et al., 2008), PicTar (Krek et al., 2005) and
DIANA (Maragkakis et al., 2009). From the three computational
algorithms, a combined precision f(t) was calculated from each
precision score, Pi. From DIANA, a precision score indicates that the
probability that the prediction is correct (the ratio of true positives
(TP) over the sum of true positives and false positives (FP), or (TP/
(TP þ FP)). In DIANA, the average number of targets for mock
miRNAs provided an estimate of the FP. In TargetScan the aggregate
Pct score is the combined probability of all predicted target sites for
a given miRNA to a target). Instead of a probability, PicTar provides
a single score value. We convert this into a precision estimate by
normalizing all prediction scores over the highest score.
For a target miRNA-target, assuming all precision scores in each
database are independent, the combined precision score, f(t) is
denoted by (Goh et al., 2011):
f(t) ¼ 1 e (1 e PDIANA) (1 e PTargetScan) (1 e PPicTar)
2.10. Western Blotting
Dissected visual cortices and primary neuronal cultures were
used. Whole cell lysates from these tissues were extracted and
quantiﬁed (20 mg). Immunoblots were blocked with Odyssey
blocking buffer (Li-Cor Biosciences) and probed with the appro-
priate dilutions of primary and secondary antibodies in Odyssey
blocking buffer with supplementation by 0.05% Tween-20. The
speciﬁcity of the antibodies was conﬁrmed by western blot. The
immunoreactive bands were visualized with Odyssey (Li-Cor Bio-
sciences). Equal protein loading was veriﬁed by anti-b-tubulin
antibody. The intensity of the western blot protein bands was car-
ried out with Image J.
2.11. cAMP assay
The cAMP standard and reaction solutions were prepared ac-
cording to manufacturer's protocol and added to the cell lysate.cAMP antibody was then added and left to incubate at room tem-
perature for 2 h. The amount of chemiluminescence was measured
on a chemiluminescent plate reader (Promega).
2.12. GenBank accession numbers
The miRNAs and proteomics discussed in this publication have
been deposited in NCBI's Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO se-
ries accession number (TBA).
2.13. Statistics
To evaluate qPCR andwestern blotting, we used GraphPad Prism
6. Signiﬁcance evaluation is based on the paired-Student's t-test
and corrected for multiple testing.
3. Results
3.1. Valproic acid differentially regulates microRNAs proﬁle in
mouse visual cortices
Valproic acid (VPA) has been shown to modulate epigenome
landscape, such as HDAC inhibition, DNA methylation and miRNAs,
thus changing gene expression to affect synaptic plasticity (Chuang
and Jones, 2007; Goh et al., 2011; Putignano et al., 2007; Silingardi
et al., 2010). We previously predicted through bioinformatics that
miRNAs and proteineprotein interaction network are dysregulated
after VPA administration in the visual cortices (Goh et al., 2013; Goh
et al., 2011). We ﬁrst investigated the global changes in miRNAs in
visual cortices after 2 h and 2 days of either vehicle (Veh 2h, Veh 2d)
or valproic acid (VPA 2h, VPA 2d) administration using a commer-
cial microarray analysis (Exiqon). The data is hierarchically clus-
tered and cross-compared against the time points and treatments.
VPA treatment produces a marked and distinctive expressional
response that Veh samples are clearly segregated from the VPA
samples (Suppl. Fig. 1). We next analyzed the differentially regu-
lated miRNAs from the 2 day experiment (188 in total) using a two-
sided t-test (p  0.05) and segregated them into signiﬁcantly up-
and down-regulated lists according to their p-value. Most of the
miRNAs were up-regulated (136 out of 188; 72.3%, white sector,
Fig. 1a) while 52 miRNAs were down-regulated (27.7%, black sector,
Fig. 1a). We next selected four candidate up-regulated miRNAs,
miR-22, miR-33a, miR-124 andmiR-132 from themicroarray, based
on their ranking in the hierarchical clustering and their z-scores
(Fig. 1b; miR-22: 11th; miR-124: 12th; miR-132: 53rd; miR-33awas
interestingly not present with Veh and only up-regulated with
VPA). Using a different set of Veh- or VPA-treated samples from
those used in the microarray (n ¼ 4 per treatment group), we
conﬁrmed their up-regulation in vivo by real-time-qPCR analysis. In
agreement with the microarray data, miR-22 and miR-124 were
signiﬁcantly up-regulated (p ¼ 0.0351 and p ¼ 0.0229 respectively)
and to a lesser extent, miR-33a and miR-132 (p ¼ 0.0583 and
p ¼ 0.0592 respectively; Fig. 1c).
3.2. VPA also up-regulates candidate miRs-22, -33a, 124
and 132 in vitro
Parallel to our in vivo study, we stimulated 3 DIV mouse primary
cortical neuronal culture with 5 mM VPA for 12 h and tested the
selected miRNAs. This dose has been shown to epigenetically
induce neuronal activity genes in vitro (Fukuchi et al., 2009).
Indeed, all the candidate miRs-22, -33a, -124 and 132 were
signiﬁcantly up-regulated in vitro, agreeing with our in vivo data
(Fig. 1d; miR-22, p ¼ 0.0171; miR-22a, p ¼ 0.0338; miR-124,
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Fig. 1. Valproic acid differentially regulates microRNAs expression proﬁle in both mouse visual cortices and primary neuronal cortical culture. (a) Pie chart showing differential
expression of microRNAs (miRNAs) in vivo after 2 days of vehicle (Veh 2d) or valproic acid (VPA 2d) administration (up-regulated, white sector; down-regulated; black sector)
obtained from microarray analysis. (b) Heat map representation of candidate miRNAs after Veh 2d or VPA 2d in vivo (blue, low expression; pink, high expression; each
rectangle ¼ biological replicate; n ¼ 4 per treatment). (c) Validation of candidate miRNAs by real-time qPCR in vivo after Veh 2d or VPA 2d. (d) Validation of candidate miRNAs by
real-time qPCR in vitro after Veh or VPA treatment (Veh, white bars, n ¼ 3; VPA, black bars, n ¼ 3). Data are represented as means ± s.e.m., normalized to 5S and U6 and relative to
Veh, *p  0.05. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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3.3. VPA differentially regulate global proteomic proﬁle in mouse
visual cortices
We compared the proteomic proﬁle in mouse visual cortices
between Veh 2d and VPA 2d. The isobaric tags for relative and ab-
solute quantitation (iTRAQ) is a technique that allows a compre-
hensive comparative quantitative determination of protein
expression from different sources in a single experiment. Nuclei-
extracted proteins obtained from Veh- and VPA-treated dissected
visual cortices (2 sets of 6e8 pooled samples in each treatment-
total of 4 samples or lanes, with 200 mg protein per lane) were
labeled into a 4-plex iTRAQ. The averaged differential scores from
the two sets of pooled visual cortices proteins were calculated and
segregated into either the up-regulated group with an average
score over 1.25 or into the down-regulated group with an average
score of less than 0.75. A total of 147 proteins met this criterion and
83 proteins were up-regulated (56.5%, white sector, Fig. 2a) while
64 proteins were down-regulated (43.5%, black sector, Fig. 2a).
3.4. miRNA-124 in silico prediction identiﬁes GNAI1 as protein
target
In order to have a better precision in predicting a regulatory
microRNA to a target protein, we combined the predictions
from three different in silico algorithms: TargetScan (http://www.
targetscan.org/), PicTar (http://pictar.mdc-berlin.de/), and DIANA
(http://diana.cslab.ece.ntua.gr) for all the four miRNAs against
the down-regulated protein list obtained from iTRAQ. Among
the four miRNAs, miR-124 gave the highest conﬁdence score, based
from its ranking on the microarray data and also its qPCR validationin both in vivo and in vitro systems. miR-124 is the most abundant
in the brain (Lagos-Quintana et al., 2002) and its expression
is initiated upon different stages of neuro-genesis, -differentiation
and -maturation in normal development (Lim et al., 2005; Makeyev
et al., 2007), (Cao et al., 2007; Cheng et al., 2009;
Papagiannakopoulos and Kosik, 2009; Sanuki et al., 2011;
Visvanathan et al., 2007). Perturbation of miR-124 has been
implicated in psychosis and neurodegenerative disorders (Das
et al., 2013; Gong et al., 2013).
To date, target proteins of miR-124 are still not completely
elucidated. Many of these are predicted based on a variety of
techniques. However, most current miRNA-target prediction en-
gines lack corroboration with each other, and the general accuracy
is not known. To gain conﬁdence in miR-124 targets, we combined
the precisions f(t) from three databases (DIANA, PicTAR and Tar-
getScan) and cross-referenced them against our known differential
proteomic list, which led us identify guanine nucleotide binding
protein alpha inhibitor 1 (GNAI1) as a miR-124 target. GNAI1, or
sometimes referred to as Gai1, is an adenylate cyclase inhibitor,
which subsequently decreases the metabolism of ATP to cAMP. The
cAMP is a second messenger and mediator of the cAMP/PKA/CREB
pathway. Fig. 2b shows the given scores from each prediction al-
gorithm speciﬁcally for miR-124 targeting GNAi1: DIANA has a
score of 0.67 or 67% chance that the prediction is correct; Tar-
getScan reports an aggregate Pct score or the combined probability
of all predicted target sites for a given miRNA to a target of 0.6154;
PicTar provides a single score value of 37, which we normalized
over the highest score in the prediction data set, to 0.19. We assume
that the precision scores are independent and combined precision,
or f(t) for miR-124 to target GNAI1 is 0.9 or 90% conﬁdence. A point
to note is that even with a high f(t), it may not translate directly to
actual biological situations as such prediction engines are never
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Fig. 2. VPA downregulates GNAI1 protein in vivo and in vitro. (a) Pie chart showing the differential expression of proteins in vivo after Veh 2d or VPA 2d obtained from iTRAQ analysis
(up-regulated, white sector; down-regulated, black sector). (b) Candidate down-regulated protein, Guanine Nucleotide binding protein, Alpha Inhibiting 1 (GNAI1), was predicted in
silico with TargetScan, PicTar and DIANA databases to be the potential target protein of miR-124. (c) Schematic miR-124 binding site of GNAI1 sequence. (d) Validation of Gnai1 by
real-time qPCR in vivo after Veh 2d or VPA 2d. Gnai1 mRNA slightly decreases. (e) Validation of Gnai1 by real-time qPCR in vitro after Veh or VPA treatment. Gnai1 mRNA does not
change. (f) Reduction in GNAI1 protein in vivo after Veh 2d or VPA 2d. (g) Signiﬁcant reduction of GNAI1 protein in vitro VPA treatment (Veh, white bars, n ¼ 3; VPA, black bars,
n ¼ 3). Data are represented as means ± s.e.m., normalized to 18S and Gapdh or bIII-tubulin and relative to Veh, *p < 0.05.
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data, which we did in the following ﬁgures, using the in vitro sys-
tem. We schematically depict the binding site location for miR-124
to the 30 end of GNAI1 (Fig. 2c) that could repress its post-
translation.
3.5. Translation of Gnai1 is affected after VPA administration
To understand if the down-regulation of GNAI1 protein is at the
transcription or the translation level, we next checked the
expression of Gnai1 mRNA both in vivo and in vitro after VPA
administration. Therewas no signiﬁcant decrease inmRNA levels in
both in vivo and in vitro conditions (Fig. 2d and e, n ¼ 3; p ¼ 0.1089,
p ¼ 0.8278, respectively). We also checked the GNAI1 protein level
in both the mouse visual cortices and in primary neuronal cultures.
Indeed, GNAI1 was signiﬁcantly decreased in both in vivo (Fig. 2f,
n¼ 4, p¼ 0.0253) and in vitro (Fig. 2g, n¼ 3, p¼ 0.0402) conditions.
This suggests that translational repression, and not transcriptional
repression of Gnai1 was affected after VPA administration.
3.6. Selective inhibition of miRNA-124 regulate GNAI1 protein
in vitro
To investigate the direct relationship of miR-124with GNAI1, we
pretreated the primary neuronal culture with a selective miR-124
inhibitor. We conﬁrmed the efﬁcacy of the miR-124 inhibitor and
3 DIV neuronal cultures pretreated with miR-124 inhibitor have
lower miR-124 expression level (Fig. 3a, n ¼ 3, p ¼ 0.0059). Next,
we prepared whole cell protein lysates and checked the GNAI1protein expression level by western blotting analysis. With the
inhibition of miR-124, GNAI1 protein was increased (Fig. 3b, n ¼ 7,
p ¼ 0.0504).
3.7. Selective miRNA-124 mimic regulate GNAI1 protein in vitro
To further verify the direct relationship of miR-124 with GNAI1,
we also pretreated primary neuronal culture with a selective miR-
124 mimic and observed a signiﬁcant increase in miR-124 expres-
sion level (Fig. 3c, n ¼ 3e4, p ¼ 0.0257). We checked the GNAI1
protein expression level in whole cell lysates by western blot and
GNAI1 was signiﬁcantly decreased after miR-124 mimic treatment
(Fig. 3d, n ¼ 4, p ¼ 0.0320).
3.8. VPA increases cAMP and Bdnf expression
As GNAI1 is an adenylate cyclase inhibitor, its reduction should
increase the levels of adenylyl cyclase activity. We next checked on
the levels of cyclic adenosine 30, 50 emonophosphate (cAMP) after
VPA stimulation and it was indeed increased after VPA stimulation
(Veh: white bar; 5 mM VPA treatment: black bar, Fig. 4a, n ¼ 3,
p¼ 0.0743). We tested out the relationship of cAMP tomiR-124 and
GNAI1 and we found that the inhibition of miR-124 decreased
cAMP levels and cAMP levels subsequently increased by 4-fold
when GNAI1 was inhibited (Veh: white bar; 5 mM VPA treat-
ment: black bar, Fig. 4b and c, n ¼ 3, p ¼ 0.0563, p ¼ 0.026).
cAMP is a critical modulator of synaptic plasticity and its acti-
vation stimulates adenylyl cyclases to induce downstream gene
transcription, such as brain-derived neurotrophic factor or BDNF
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nerve growth factor that increases neurogenesis and synaptic
plasticity (Einat et al., 2003; Laeng et al., 2004; Rosenberg, 2007).
We then checked Bdnf mRNA expression after Veh or VPA admin-
istration and found their levels to be enhanced (Veh: white bar;
5 mM VPA treatment: black bar, Fig. 4d, n ¼ 3e4, p ¼ 0.0436). We
investigated if reduction of miR-124 or GNAI1 would affect the
expression levels of Bdnf. Indeed, we found Bdnf mRNA was
decreased with miR-124 inhibition but increased with Gnai1 siRNA
by 2.5-fold (Veh: white bar; 5 mM VPA treatment: black bar, Fig. 4e
and f, n ¼ 3, p ¼ , p ¼ 0.0007).
3.9. Inhibition of miR-124 prevents GNAI1 down-regulation after
VPA in vitro
To test if miR-124 is important in regulating the levels of GNAI1or BDNF, we pretreated primary neuronal cultures with miR-124
inhibitor and applied either Veh or 5 mM VPA to them. After a
12-h stimulation, the cells were harvested and whole cell protein
samples were extracted for western blot analysis. Thus, pre-
treatment of miR-124 inhibitor block miR-124 expression that
prevent GNAI1 and Bdnf expression, even in the presence of VPA
(Veh:white bar; 5mMVPA treatment: black bar, Fig. 5a and c, n¼ 3,
p ¼ 0.733, p ¼ 0.917 respectively). This experiment strengthens the
link between that miR-124-GNAI1-Bdnf cascade.
We then added VPA to primary neuronal culture pretreatedwith
miR-124 mimic and checked the GNAI1 protein expression level.
The addition of miR124 mimic further enhanced the reduction of
GNAI1 protein level after VPA stimulation, suggesting that miR-124
directly repress GNAI1 protein translation and conversely upregu-
lates Bdnf mRNA (Veh: white bar; 5 mM VPA treatment: black bar,
Fig. 5b and d, n ¼ 3, p ¼ 0.0053 and p ¼ 0.0277). This strengthens
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GNAI1.
4. Discussion & conclusions
This study generated ﬁve main ﬁndings: 1) VPA induces miR-
124 and down-regulates GNAI1; 2) miR-124 mimic down-
regulates GNAI1 whilw inhibiting miR-124 increases GNAI1; 3)
VPA activates cAMP and induces Bdnf and this pathway can also be
induced with Gnai siRNA knockdown; 4) VPA, miR-124 mimic and
Gnai1 siRNA knockdown gives rise to BdnfmRNA transcription and
the converse with miR-124 inhibition; whereas 5) inhibiting miR-
124 abolishes the downstream pathway. Based on our ﬁndings,
we schematically depict the molecular mechanisms underlying
VPA and its effects on BDNF (Fig. 6). After receiving VPA stimulation,
miR-124 is induced in nucleus (Fig. 6-1). The induced miR-124
subsequently down regulates GNAI1 expression (Fig. 6-2) and in-
creases adenylyl cyclases activity to elevate cAMP concentration
(Fig. 6-3 and 6-4). The elevated cAMP activates signaling pathways
causing a downstream gene transcription that increases Bdnf
expression (Fig. 6-5). There could be signaling pathways that acti-
vate Bdnf could be further investigated.
Despite using VPA in clinical settings for the last few decades, its
exact mechanism is still unknown. While it is mainly used as an
anticonvulsant, VPA has been shown to have other therapeutic ef-
fects such as anti-tumorogenesis, neuroprotective, promoting
neurogenesis, differentiation and neuroregeneration and
improving synaptic plasticity (Abematsu et al., 2010; Foti et al.,
2013; Fukuchi et al., 2009; Hao et al., 2004; Jessberger et al.,
2007; Laeng et al., 2004; Liu et al., 2012; Morris and Monteggia,
2013; Phiel et al., 2001). We are interested in the underlying mo-
lecular mechanism of VPA that increases neuroplasticity. Studies
have shown that VPA induces neurotrophins, in particular, brain-
derived neurotrophic factor (BDNF) (Nishino et al., 2012). BDNF iswell established to direct growth and differentiation in the devel-
oping nervous system, promotes neurogenesis and dendritic spine
reorganization and activity-dependent plasticity in adult brain
[16e18(Nishino et al., 2012). Thus, we elucidated the molecular
mechanism of VPA and its mediation of Bdnf transcription.
VPA has been reported to induce epigenetic changes such as
inhibiting histone deacetylases and inducing microRNAs that
modulate gene expression changes (Goh et al., 2011; Hunsberger
et al., 2012; Jessberger et al., 2007; Tremolizzo et al., 2005; Zhou
et al., 2008). The interplay between HDACs and miRNAs is tightly
regulated and is evident from our recent report, whereby we pre-
dicted in silico the miRNAs network that interact and disrupt pro-
tein complexes after VPA administration (Goh et al., 2011). While
VPA is a pan-HDAC inhibitor that inhibits both class I and IIa HDAC
enzymes (Jessberger et al., 2007; Tremolizzo et al., 2005; Yasuda
et al., 2009), we and other groups have shown that VPA induces
miRNAs in the brain (Hunsberger et al., 2012; Zhou et al., 2008). It is
likely that miRNAs could affect epigenetic machinery and in turn,
miRNA expression could also be controlled by other epigenetic
mechanisms not explored in this study.
The ﬁrst important ﬁnding from our study is identifying VPA-
mediated up-regulation of miR-124 targeting at GNAI1 (Figs. 1
and 2). First, the change in miRNAs after VPA administration were
screened and the data segregates very well into the respective
treatment groups (Suppl. Fig. 1). We validated the VPA-induced
miRNAs in both in vivo and in vitro systems (Fig. 1). miRNAs
comprise short noncoding RNA that regulate gene expression post-
transcriptionally and many of their target proteins are usually
predictive but lacking a solid benchmark of their exact precisions.
Thus, to gain conﬁdence of our ﬁndings, we used a combination of
algorithms and we cross-referenced them against our known dif-
ferential proteomic list. This led to ﬁnding miR-124 targeting gua-
nine nucleotide binding protein alpha inhibitor 1 protein (GNAI1,
Fig. 2b), an adenylyl cyclase inhibitor (Bromberg et al., 2011; Pineda
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2005). By using either miR-124 mimic or inhibitor, the levels of
GNAI1 either down- or up-regulate, respectively, further support-
ing their relationship (Fig. 3).
Heterotrimeric G-proteins transduce molecular signals from
hormones, neurotransmitters, and chemokines and convert them
into intracellular responses through G-protein coupled receptors to
modulate physiological functions, such as learning and memory
(Bromberg et al., 2011; Wettschureck and Offermanns, 2005). G-
proteins consist of alpha, beta, and gamma subunits and the alpha
subunit plays an important role in binding guanine nucleotides to
hydrolyze GTP to GDP. There are about twenty different aesubunits
identiﬁed in the mammalian heterotrimeric G-protein superfamily
and ubiquitously expressed in the brain (Bromberg et al., 2011;
Wettschureck and Offermanns, 2005). GNAI1 is an adenylyl
cyclase inhibitor and its inhibition will cause the accumulation of
cAMP within the cell. The ablation of GNAI1 has been shown to
increase hippocampal adenylyl cyclase activity and enhances long-
term potentiation (LTP) in area CA1 (Pineda et al., 2004). cAMP is a
critical modulator of synaptic plasticity and is known to induce
gene transcription by mediating through activation of cAMP to
activate downstream gene transcription. BDNF is a well-known
neurotrophin that is important in neurogenesis (Mizuno et al.,2002; Rosenberg, 2007). In fact, chronic concomitant administra-
tion of VPA and lithium modulates neuroplasticity molecules
through the BDNF transcription (Nishino et al., 2012). We obtained
similar result in our 2-day VPA treatment in vivo (manuscript in
submission). We propose that VPA induces miR-124 that inhibits
GNAI1. This leads to increase cAMP level and increase in Bdnf
transcription.
The association between miR-124 and BDNF has previously
been established (Nishino et al., 2012). While we and other groups
have shown that VPA treatment inducedmiR-124 and consequently
increased Bdnf (Fig. 4def), we wanted to verify if the up-regulation
of Bdnf is a result of miR-124. With a miR-124 inhibitor, Bdnf
transcription decreased (Fig. 4e). Even in the presence of VPA, miR-
124-inhibited primary cortical cultures could not increase Bdnf,
suggesting that miR-124 is needed for the VPA induced up-
regulation of Bdnf (Fig. 5c). In addition, we demonstrated the next
important ﬁnding where GNAI1 acts as an intermediary from miR-
124 to BDNF. By knocking down GNAI1 with siRNA, levels of BDNF
can be increased (Fig. 4f), suggesting the role of GNAI1 in BDNF
regulation, thoughwe cannot rule out that there are other signaling
pathways that may activate cAMP independent of GNAI1. Taken
together, our ﬁndings support the role of both miR-124 and GNAI1
in BDNF regulation. Since changes in the levels and activities of
VPA 
5;Increase in BDNF expression 
4; Increase cAMP 
2; Decrease GNAI1 expression 
3; Enhancement adenylyl cyclases 
1; miR-124 induction 
GNAI1 
Stimulation 
?? 
Fig. 6. Schematic representation of the molecular mechanistic action of VPA mediated through miR-124 and reduction of GNAI1 protein. Upon VPA stimulation, miR-124 is induced
and binds to 30UTR sequence of Gnai1 protein. This, in turn, down-regulates GNAI1 protein synthesis. The reduced GNAI1 increases cAMP, which in turn, increases BDNF after VPA
stimulation. There are additional signaling pathways, which may activate BDNF.
H. Oikawa et al. / Neurochemistry International 91 (2015) 62e7170BDNF have been described in a number of neurodegenerative dis-
orders, we also checked GNAI1 protein expression level in a mouse
model of Huntington's disease. Preliminary results show that
GNAI1 protein was signiﬁcantly increased in the cerebral cortices
(unpublished data, data not shown). This suggests the possible
usage of either miR-124 inhibitor or Gnai1 siRNA in the treatment
of neurodegenerative diseases through elevation of BDNF levels.
In summary, we have identiﬁed a molecular mechanism
through VPA that induces BDNF under miR-124 control and its
target protein, GNAI1. In the last few years, the National Clinical and
Translational Science (http://www.ncats.nih.gov/) has been
collaboratively testing new therapeutic uses for existing pharma-
ceutical agents in a drug-repurposing program. With the available
information on the pharmacology, formulation and potential
toxicity of VPA, this may prove to be easier for its integration into
health care therapy for neurological diseases and beyond its current
use in epilepsy and depression.
The implication of miR-124/GNAI1/BDNF pathway with
valproic acid treatment suggests that we could repurpose an old
drug, valproic acid, as a clinical application to elevate neurotrophin
levels in treating neurodegenerative diseases. This study represents
only the ﬁrst steps toward the unique mechanisms used bymiRNAs
and their target transcripts. Nonetheless, it contributes to our un-
derstanding of miRNAs and their functions in regulatory to gener-
ation sequencing, its accessibility and cost-effectiveness, selective
screening of miRNAs directly on the human transcriptomic” maybecome a routine procedure for diagnosis and personalized medi-
cine in the near future.
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